SMARCB1 is known to be disrupted in malignant rhabdoid tumors, round cell soft-tissue sarcomas (most were a subset of tumors resembling extraskeletal myxoid chondrosarcoma with rhabdoid features, epithelioid sarcomas, and schwannomatosis [34]–[38]. Here, SMARCB1 is linked to rhabdoid tumor.